Omnicell (NASDAQ:OMCL - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.300-0.370 for the period, compared to the consensus estimate of 0.304. The company issued revenue guidance of $290.0 million-$300.0 million, compared to the consensus revenue estimate of $284.1 million. Omnicell also updated its FY 2025 guidance to 1.400-1.650 EPS.
Analyst Ratings Changes
Several equities research analysts have weighed in on the company. Benchmark cut their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Bank of America upped their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Finally, Wall Street Zen raised shares of Omnicell from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 12th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Omnicell has a consensus rating of "Moderate Buy" and an average price target of $45.33.
Check Out Our Latest Analysis on OMCL
Omnicell Price Performance
Shares of OMCL traded down $1.25 during trading hours on Friday, reaching $29.76. The company had a trading volume of 742,476 shares, compared to its average volume of 500,803. The firm has a 50 day simple moving average of $29.27 and a 200-day simple moving average of $33.18. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 59.52, a PEG ratio of 9.05 and a beta of 0.76. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.74.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm's revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.51 EPS. Research analysts expect that Omnicell will post 1.09 earnings per share for the current year.
Institutional Trading of Omnicell
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC increased its position in Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock worth $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after purchasing an additional 4,866 shares in the last quarter. AQR Capital Management LLC increased its position in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock worth $627,000 after purchasing an additional 5,311 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after buying an additional 109,382 shares during the period. Hedge funds and other institutional investors own 97.70% of the company's stock.
Omnicell Company Profile
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Stories
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
